The safest interpretation is that 5-Amino-1MQ is an early-stage research compound with possible metabolic relevance, not a proven replacement for medical treatment, nutrition, exercise, sleep, or provider-guided weight-loss care
MOTS-c mitochondrial-derived peptide cross-referenced in metabolic-rate research
Pregnancy and Breastfeeding: If you are pregnant, planning to become pregnant, or breastfeeding, consult with a healthcare provider before using any peptides
inhibition explored in preclinical metabolic research Oral bioavailability demonstrated in animal models Research Status: 5-Amino-1MQ is in early preclinical stages with limited published research
2015. MOTS-c promotes metabolic homeostasis and reduces obesity/insulin resistance
received advisory/consulting fees and/or other support from Altimmune, AstraZeneca, Bayer, Biomea, Boehringer Ingelheim, Carmot Therapeutics, Cytoki Pharma, Eli Lilly, Intercept, Janssen/Johnson & Johnson, Mannkind, Mediflix, Merck, Metsera, Novo Nordisk, Pharmaventures, Pfizer, Regeneron, Sanofi, Shionogi, Structure Therapeutics, Target RWE, Terns Pharmaceuticals, The Comm Group, Valeritas, WebMD and Zealand Pharma
